Jean Saslawsky | CEO
EURORDIS - Rare Diseases Europe

Jean Saslawsky, CEO, EURORDIS - Rare Diseases Europe

Jean Saslawsky is Chief Executive Officer of EURORDIS-Rare Diseases Europe, the independent
voice representing people living with rare diseases across Europe. He joined EURORDIS in June
2026, bringing more than 25 years of leadership experience across the health, humanitarian and
social impact sectors.
Before joining EURORDIS, Jean served as Director of Programs, Operations and Advocacy at CARE
France, where he led international operations across 50 countries and advocacy engagement with
French and European decision-makers. He previously served as Secretary General of the
international network of Médecins du Monde (Doctors of the World), coordinating 15 national
organisations across Europe, the Americas and Asia and helping to develop the network’s first
global strategy.
Jean has also served as Director General of Fondation La France s’engage, supporting social
innovation and strengthening partnerships with companies and philanthropic organisations.
Throughout his career, Jean has worked at the intersection of health, international cooperation,
advocacy and organisational development. He began his career in humanitarian field operations,
including assignments in Bosnia and Georgia, experiences that shaped his long-standing
commitment to public service and solidarity.

Appearances:



Day 1 @ 09:00

Keynote panel: EU Pharmaceutical Legislation Revision – what’s new for 2026?

-       How will the revision affect rare diseases?

-       Navigating Europe’s regulatory incentives and the future of pharmaceutical R&D innovation

-       Who do we ensure that changes can facilitate Europe’s access, innovation and sustainability?

-       The European Biotech Act and its impact on rare diseases

Day 2 @ 09:45

Keynote Panel: How are patients involved in every step of the orphan drug development and global access?

-       Patient led solutions to orphan drug development and access bottlenecks

-       How to solve the issue of small patient populations through statistical innovation, regulatory flexibility and patient-centricity

-       Utilising Real-World Data and natural history studies

-       Creating meaningful endpoints that improves patients’ quality of life

last published: 23/Oct/26 18:03 GMT

back to speakers

Get involved at World Orphan Drug Congress Europe 2026

 

 

TO SPONSOR


Steph Scanlon

Steph.Scanlon@terrapinn.com

 

TO SPEAK


Abdu Kauroo
Abdu.Kauroo@terrapinn.com

 

MARKETING & PRESS


Jasper Cameron

Jasper.Cameron@terrapinn.com